What are Peptide Therapeutics?
Definition
Peptide therapeutics are a class of pharmaceutical drugs composed of short chains of amino acids, typically between 2 and 50 residues in length. They occupy a unique niche between small-molecule drugs and large biologic proteins, combining the target specificity of antibodies with improved tissue penetration and lower manufacturing costs. The global peptide therapeutics market exceeded $50 billion in 2023 and is projected to grow at 9-10% annually.
Detailed Explanation
Over 80 peptide drugs have been approved by the FDA as of 2024, treating conditions ranging from diabetes (semaglutide, liraglutide) and cancer (leuprolide, octreotide) to rare diseases (teduglutide for short bowel syndrome) and cardiovascular conditions (bivalirudin). The recent commercial success of GLP-1 receptor agonists — particularly semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) — has transformed the peptide therapeutics landscape, with combined annual sales exceeding $30 billion. This commercial validation has driven massive investment in peptide drug discovery platforms and manufacturing infrastructure.
Peptides offer distinct advantages over both small molecules and large biologics. Compared to small molecules, peptides achieve higher target selectivity (fewer off-target effects), can target protein-protein interactions that are undruggable by small molecules, and are biodegradable into natural amino acids (reducing toxicity concerns). Compared to antibodies, peptides have lower manufacturing costs, better tissue penetration, multiple administration routes (injection, oral, nasal, transdermal), and can be chemically synthesized via Fmoc-SPPS rather than requiring cell-based production. Their key limitation has historically been short plasma half-life due to protease degradation, but modern strategies like lipidation (semaglutide), PEGylation, and cyclization have extended half-lives from minutes to weeks.
PepFold is designed specifically for the computational design of peptide therapeutic candidates. The platform generates peptide sequences that target proteins affected by a patient's pharmacogenomic variants, predicts their 3D structures using ESMFold, scores them across 10 dimensions (including binding affinity, protease resistance, ADMET properties, and synthesis feasibility), and produces ready-to-use Fmoc-SPPS protocols. This end-to-end approach accelerates the early-stage peptide drug discovery process from months of manual work to minutes of computation.
Related Terms
Fmoc-SPPS (Fluorenylmethyloxycarbonyl Solid-Phase Peptide Synthesis) is the dominant chemical method for synthesizing peptides in both research and pharmaceutical manufacturing. The peptide chain is assembled from C-terminus to N-terminus on an insoluble resin support, with each amino acid's alpha-amino group protected by the Fmoc group, which is removed with piperidine before coupling the next residue.
What are GLP-1 Receptor Agonists?GLP-1 receptor agonists (GLP-1 RAs) are a class of peptide drugs that mimic the incretin hormone glucagon-like peptide-1. They bind to and activate the GLP-1 receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite. Major examples include semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound).
What is De Novo Peptide Design?De novo peptide design is the computational creation of novel peptide sequences that do not exist in nature, engineered from scratch to achieve specific therapeutic objectives. Unlike peptide discovery from natural sources (venoms, hormones, antimicrobial peptides), de novo design uses algorithms, molecular modeling, and machine learning to generate sequences optimized for target binding, stability, selectivity, and manufacturability.
What is Binding Affinity?Binding affinity is a quantitative measure of the strength of interaction between two molecules, typically a drug (ligand) and its biological target (receptor or protein). It is most commonly expressed as the dissociation constant (Kd), which represents the concentration of ligand at which 50% of the target binding sites are occupied. A lower Kd indicates stronger binding — nanomolar (nM) or picomolar (pM) affinities are typical for effective drugs.
Apply This Knowledge with PepFold
Submit rsIDs and get ranked peptide candidates with 3D structures and Fmoc-SPPS synthesis protocols in under 2 minutes.